Online inquiry

IVTScrip™ mRNA-Anti-CD37, K7153A(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ9858MR)

This product GTTS-WQ9858MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CD37 gene. The antibody can be applied in Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001040031.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 951
UniProt ID P11049
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD37, K7153A(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ9858MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13990MR IVTScrip™ mRNA-Anti-GP, REGN-3470-3471-3479(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA REGN-3470-3471-3479
GTTS-WQ9497MR IVTScrip™ mRNA-Anti-EGFR, J2898A(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA J2898A
GTTS-WQ3391MR IVTScrip™ mRNA-Anti-Canlupfam CD52, AT-005(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AT-005
GTTS-WQ7078MR IVTScrip™ mRNA-Anti-FAP, FAP-IL2v(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA FAP-IL2v
GTTS-WQ14786MR IVTScrip™ mRNA-Anti-CD40, SGN-40(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA SGN-40
GTTS-WQ8209MR IVTScrip™ mRNA-Anti-SLC39A6, hLIV22(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA hLIV22
GTTS-WQ3479MR IVTScrip™ mRNA-Anti-pcrV, BA1126(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA BA1126
GTTS-WQ2627MR IVTScrip™ mRNA-Anti-IL2RB, AMG 592(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA AMG 592
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW